<DOC>
	<DOC>NCT00618774</DOC>
	<brief_summary>To assess the long term safety and efficacy of telmisartan plus amlodipine FDC in patients with essential hypertension who failed to control their BP with either monotherapy</brief_summary>
	<brief_title>An Open-label, Long-term Study of Telmisartan Plus Amlodipine Fixed-dose Combination</brief_title>
	<detailed_description />
	<mesh_term>Telmisartan</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>1. Patients with essential hypertension 2. Outpatient Patients whose SBP &gt;=180 mmHg or DBP &gt;=110 mmHg at the end of treatment visit of the doubleblind treatment period in the "nonresponder trials" Patients who have met any of the exclusion criteria defined in the "nonresponder trials"</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>